ALT
Price
$4.08
Change
-$0.03 (-0.73%)
Updated
Jul 25 closing price
Capitalization
330.92M
11 days until earnings call
NBY
Price
$0.67
Change
+$0.02 (+3.08%)
Updated
Jul 25 closing price
Capitalization
3.91M
Interact to see
Advertisement

ALT vs NBY

Header iconALT vs NBY Comparison
Open Charts ALT vs NBYBanner chart's image
Altimmune
Price$4.08
Change-$0.03 (-0.73%)
Volume$2.97M
Capitalization330.92M
NovaBay Pharmaceuticals
Price$0.67
Change+$0.02 (+3.08%)
Volume$118.09K
Capitalization3.91M
ALT vs NBY Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. NBY commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and NBY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ALT: $4.11 vs. NBY: $0.67)
Brand notoriety: ALT and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 0% vs. NBY: 342%
Market capitalization -- ALT: $330.92M vs. NBY: $3.91M
ALT [@Biotechnology] is valued at $330.92M. NBY’s [@Biotechnology] market capitalization is $3.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while NBY’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • NBY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALT is a better buy in the short-term than NBY.

Price Growth

ALT (@Biotechnology) experienced а +0.74% price change this week, while NBY (@Biotechnology) price change was +1.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

ALT is expected to report earnings on Nov 11, 2025.

NBY is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($331M) has a higher market cap than NBY($3.91M). NBY YTD gains are higher at: 11.876 vs. ALT (-42.996). NBY has higher annual earnings (EBITDA): -6.8M vs. ALT (-90.75M). ALT has more cash in the bank: 150M vs. NBY (8.47M). NBY has less debt than ALT: NBY (1.13M) vs ALT (1.59M). NBY has higher revenues than ALT: NBY (9.78M) vs ALT (20K).
ALTNBYALT / NBY
Capitalization331M3.91M8,463%
EBITDA-90.75M-6.8M1,334%
Gain YTD-42.99611.876-362%
P/E RatioN/A0.03-
Revenue20K9.78M0%
Total Cash150M8.47M1,772%
Total Debt1.59M1.13M141%
FUNDAMENTALS RATINGS
ALT vs NBY: Fundamental Ratings
ALT
NBY
OUTLOOK RATING
1..100
7866
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9712
PRICE GROWTH RATING
1..100
9456
P/E GROWTH RATING
1..100
10038
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (13) in the Biotechnology industry is significantly better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew significantly faster than ALT’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew similarly to ALT’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew significantly faster than ALT’s over the last 12 months.

NBY's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for ALT (94) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew somewhat faster than ALT’s over the last 12 months.

NBY's P/E Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for ALT (100) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew somewhat faster than ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTNBY
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RBGLY15.140.06
+0.40%
Reckitt Benckiser Group Plc.
ELCO42.25N/A
N/A
Elcom International, Inc.
SBWFF0.11N/A
N/A
CORNISH METALS INC
KINUF30.23N/A
N/A
Kintetsu Group Hldgs Co. Ltd.
PHCCF5.98N/A
N/A
PHC Holdings Corp.